ENVOY MEDICAL, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | $241.0K | $225.0K | $316.0K | $237.0K | — |
| Cost of Revenue | — | $874.0K | $742.0K | $789.0K | $498.0K | — |
| Gross Profit | — | $-633.0K | $-517.0K | $-473.0K | $-261.0K | — |
| Gross Margin | — | -262.7% | -229.8% | -149.7% | -110.1% | — |
| Operating Expenses | ||||||
| Research & Development | — | $12.5M | $10.2M | $9.0M | $5.0M | — |
| SG&A Expense | — | $7.9M | $6.8M | $7.3M | $2.6M | — |
| Operating Income | — | $-22.3M | $-19.3M | $-18.4M | $-8.7M | $-5.2M |
| Operating Margin | — | -9,240.7% | -8,558.2% | -5,809.8% | -3,673.4% | — |
| Interest Expense | — | $1.6M | $816.0K | — | — | — |
| Pretax Income | — | $-23.8M | $-20.8M | — | $20.7M | $-251.6K |
| Income Tax Expense | — | — | — | — | $1.5M | — |
| Net Income | — | $-23.8M | $-20.8M | $-29.9M | $-15.9M | $-251.6K |
| Net Margin | — | -9,857.3% | -9,242.2% | -9,469.0% | -6,718.6% | — |
| EPS (Basic) | — | $-1.23 | $-1.49 | $-2.54 | $-1.57 | — |
| EPS (Diluted) | — | $-1.23 | $-1.49 | $-2.54 | $-1.57 | — |
| Shares Outstanding (Basic) | 76.9M | 23.3M | 18.8M | 12.3M | 10.1M | — |
| Shares Outstanding (Diluted) | 76.9M | 23.3M | 18.8M | 12.3M | 10.1M | — |
| Dividends Per Share | — | — | — | — | — | — |